• V. KEERTHANA Pharma Buddy, Faculty of Pharmacy, Dr. M. G. R Educational and Research Institute, Velappanchavadi, Chennai 600077
  • S. DHANALAKSHMI Department of Pharmacognosy, Faculty of Pharmacy, Dr. M. G. R Educational and Research Institute, Velappanchavadi, Chennai 600077
  • N. HARIKRISHNAN Department of Pharmaceutical Analysis, Faculty of Pharmacy, Dr. M. G. R Educational and Research Institute, Velappanchavadi, Chennai 600077




BBB, CNS, Brain target, Nanoparticles, TDDS, Neural diseases


Delivery of drugs into the brain is one of the most interesting and challenging areas of research. The blood-brain barrier (BBB) is a highly selective semipermeable membrane that separates blood from the brain in the central nervous system. It acts as a barrier to protect the brain from microbes, neurotoxins and other chemical substances and also blocks the entry of many drugs into the brain. An estimated 6.8 billion people die every year from CNS diseases like Parkinson’s disease, Alzheimer’s disease, sclerosis, brain stroke, dementia and others. According to WHO, one billion people are affected worldwide, about 50 million suffer from epilepsy and 24 million suffer from Alzheimer and other dementias. This indicates the importance of the delivery of drugs into the brain for treating various neurological diseases and psychological disorders. In drug targeting, a concept was introduced by Dr. Paul Ehrlich as a ‘magic bullet’ that gave tremendous hope for the researches to deliver drugs into the brain. This review discuses about various drug targeting strategies and applications of nanotechnology in designing drug delivery systems with the ability to cross through the BBB for treating neurological diseases.


Download data is not yet available.


1. M Srikanth, JA Kessler. Nanotechnology-novel therapeutics for CNS disorders. Nat Rev Neurol 2012;8:307.
2. M Vijayan, PH Reddy. Stroke, vascular dementia, and Alzheimer’s disease: molecular links. J Alzheimer Dis 2016;54:427–43.
3. Kabanov H Gendelman. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci 2007;32:1054–82.
4. Nazem GA Mansoori. Nanotechnology solutions for Alzheimer’s disease: advances in research tools, diagnostic methods and therapeutic agents. J Alzheimer Dis 2008;13:199–223.
5. P Flachenecker. Epidemiology of neuroimmunological diseases. J Neurol 2006;253:v2–v8.
6. NJ Abbott, AAK Patabendige, DEM Dolman, SR Yusof, DJ Begley. Structure and function of the blood-brain barrier. Neurobiol Dis 2010;37:13–25.
7. J Boyer Di Ponio, F El Ayoubi, F Glacial, K Ganeshamoorthy, C Driancourt, M Godet, et al. Instruction of circulating endothelial progenitors in vitro towards the specialized blood-brain barrier and arterial phenotypes. PLoS One 2014;9:e84179.
8. JD Huber, KA Witt, S Hom, RD Egleton, KS Mark, TP Davis. In?ammatory pain alters blood-brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol 2001;280:H1241–H1248.
9. H Wolburg, A Lippoldt. Tight junctions of the blood-brain barrier: development, composition and regulation. Vasc Pharmacol 2002;38:323–37.
10. Y Persidsky, SH Ramirez, J Haorah, GD Kanmogne. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neurol Immune Pharmacol 2006;1:223–36.
11. YK Choi, KW Kim. Blood–neural barrier: its diversity and coordinated cell-to-cell communication. BMB Rep 2008;41: 345–52.
12. Alvarez-Buylla, JM Garcia-Verdugo. Neurogenesis in adult subventricular zone. J Neurosci 2002;22:629–34.
13. M Tavazoie, L Van der Veken, V Silva Vargas, M Louissaint, L Colonna, B Zaidi, et al. A specialized vascular niche for adult neural stem cells. Cell Stem Cell 2008;3:279–88.
14. MC Whitman, W Fan, L Rela, DJ Rodriguez Gil, CA Greer. Blood vessels form amigratory scaffold in the rostral migratory stream. J Comp Neurol 2009;516:94–104.
15. L Bennett, M Yang, G Enikolopov, L Iacovitti. Circumventricular organs: a novelsite of neural stem cells in the adult brain. Mol Cell Neurosci 2009;41:337–47.
16. Hourai S Miyata. Neurogenesis in the circumventricular organs of adult mouse brains. J Neurosci Res 2013;91:757–70.
17. R Lin, J Cai, C Nathan, X Wei, S Schleidt, R Rosenwasser, et al. Neurogenesis is enhanced by stroke in multiple new stem cell niches along the ventricular system at sites of high BBB permeability. Neurobiol Dis 2015;74:229–39.
18. H Xin, X Sha, X Jiang, L Chen, K Law, J Gu, et al. The brain targeting mechanism of angiopep-conjugated poly(ethylene glycol)-co-poly(e{open}-caprolactone) nanoparticles. Biomaterials 2012; 33:1673–81.
19. JV Georgieva, D Kalicharan, PO Couraud, IA Romero, B Weksler, D Hoekstra, et al. Surface characteristics of nanoparticles determine their intracellular fate in and processing by human blood-brain barrier endothelial cells in vitro. Mol Ther 2011;19:318-25.
20. R Gromnicova, HA Davies, P Sreekanthreddy, IA Romero, T Lund, IM Roitt, et al. Glucose-coated gold nanoparticles transfer across human brain endothelium and enter astrocytes in vitro. PLoS One 2013;8:e81043.
21. X Gao, J Qian, S Zheng, Y Changyi, J Zhang, S Ju, et al. Overcoming the blood-brain barrier for delivering drugs into the brain by using adenosine receptor nanoagonist. ACS Nano 2014;8:3678–89.
22. P Decuzzi, B Godin, T Tanaka, SY Lee, C Chiappini, X Liu, et al. Size and shape effects in the biodistribution of intravascularly injected particles. J Controlled Release 2010;141:320–7.
23. S Aday, R Cecchelli, D Hallier Vanuxeem, MP Dehouck, L Ferreira. Stem cell-based human blood-brain barrier models for drug discovery and delivery. Trends Biotechnol 2016;34:382-93.
24. R Cecchelli, S Aday, E Sevin, C Almeida, M Culot, L Dehouck, et al. A stable and reproducible human blood-brain barrier model derived from hematopoietic stem cells. PLoS One 2014; 9:e99733.
25. H Cho, JH Seo, KHK Wong, Y Terasaki, J Park, K Bong, et al. Three-dimensionalblood–brain barrier model for in vitro studies of neurovascular pathology. Sci Rep 2015;5:15222.
26. Q Liu, J Hou, X Chen, G Liu, D Zhang, H Sun, et al. P-glycoprotein mediated ef?ux limits the transport of the novel anti-Parkinson's disease candidate drug FLZ across the physiological and PD pathological in vitro BBB models. PLoS One 2014;9:e102442.
27. Freese S Reinhardt, G Hefner, RE Unger, CJ Kirkpatrick, K Endres. A novel blood-brain barrier co-culture system for drug targeting of Alzheimer's disease: establishment by using acitretin as a model drug. PLoS One 2014;9:91003.
28. S Syvanen, O Lindhe, M Palner, BR Kornum, O Rahman, B Langström, et al. Spe-cies differences in blood-brain barrier transport of three positron emission tomog-raphy radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos 2009;37:635–43.
29. L Yang, KK Shah, TJ Abbruscato. An in vitro model of ischemic stroke. Methods Mol Biol 2012;814:451–66.
30. B Etame, CA Smith, WC Chan, JT Rutka. Design and potential application of PEGylated gold nanoparticles with size-dependent permeation through brain microvasculature. Nanomedicine 2011;7:992–1000.



How to Cite

KEERTHANA, V., S. DHANALAKSHMI, and N. HARIKRISHNAN. “A PERSPECTIVE REVIEW ON APPLICATIONS OF NANOPARTICLE MEDIATED DRUG DELIVERY TO THE CNS”. International Journal of Current Pharmaceutical Research, vol. 12, no. 1, Jan. 2020, pp. 1-4, doi:10.22159/ijcpr.2020v12i1.36819.



Review Article(s)